Telix (TLX) COO reports ordinary shares, ADRs and option-like awards
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Telix Pharmaceuticals Ltd Group Chief Operating Officer Darren Joel Patti filed an initial ownership report showing existing equity interests in the company. The filing lists 25,558 Ordinary Shares held directly and 804 American Depositary Receipts, each convertible into one ordinary share according to the footnotes.
It also discloses derivative awards over ordinary shares, including Performance Share Appreciation Rights over 15,826 shares at $4.9500 per share and 27,448 shares at $6.9000, both with future expiration dates. Share Rights cover an additional 15,000, 12,541, and 15,000 underlying ordinary shares at a $0.0000 exercise price, with vesting and exercisability tied to continued service and future testing of results. The report records holdings only and does not show new market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Patti Darren Joel
Role
Group Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Performance Share Appreciation Rights (right to buy) | -- | -- | -- |
| holding | Share Rights | -- | -- | -- |
| holding | Share Rights | -- | -- | -- |
| holding | Performance Share Appreciation Rights (right to buy) | -- | -- | -- |
| holding | Share Rights | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | American Depositary Receipts | -- | -- | -- |
Holdings After Transaction:
Performance Share Appreciation Rights (right to buy) — 15,826 shares (Direct);
Share Rights — 15,000 shares (Direct);
Ordinary Shares — 25,558 shares (Direct);
American Depositary Receipts — 804 shares (Direct)
Footnotes (1)
- Each American Depositary Receipt (ADR) is convertible at any time, at the holders election, into one ordinary share of the issuer. The ADRs have no expiration date. The performance share appreciation rights (PSARs) were granted on April 5, 2022, and became vested and excercisable on March 6, 2025. Conversion price is reported in Australian Dollars. The share rights (SRs) were granted on November 1, 2023 and will become vested and exercisable on November 1, 2026, subject to continued service with the issuer. Each SR represents the contingent right to receive one ordinary share. The SRs were granted on March 18, 2026 and will become auto-vested and exercised in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only. The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share (or ADR). See footnote (1). The PSARs were granted on May 2, 2023, and became vested and exercisable on March 12, 2026. The SRs were granted on November 1, 2023 and will become vested and exercisable on November 1, 2027, subject to continued service with the issuer. Each SR represents the contingent right to receive one ordinary share.
Key Figures
Ordinary Shares held: 25,558 shares
ADRs held: 804 ADRs
PSARs at $4.9500: 15,826 underlying shares
+4 more
7 metrics
Ordinary Shares held
25,558 shares
Directly held Ordinary Shares reported as of the Form 3 date
ADRs held
804 ADRs
American Depositary Receipts, each convertible into one ordinary share
PSARs at $4.9500
15,826 underlying shares
Performance Share Appreciation Rights, exercise price $4.9500, expiring 2027-04-04
PSARs at $6.9000
27,448 underlying shares
Performance Share Appreciation Rights, exercise price $6.9000, expiring 2027-12-21
Share Rights 2028 vesting
15,000 underlying shares
Share Rights at $0.0000 exercise price, expiring 2028-01-11
Share Rights 2027 vesting
12,541 underlying shares
Share Rights at $0.0000 exercise price, expiring 2027-03-12
Auto-vesting Share Rights
15,000 underlying shares
Share Rights at $0.0000 exercise price, expiring 2029-01-11
Key Terms
Performance Share Appreciation Rights, Share Rights, American Depositary Receipt, auto-vested, +1 more
5 terms
American Depositary Receipt financial
"Each American Depositary Receipt (ADR) is convertible at any time, at the holders election"
An American depositary receipt (ADR) is a certificate that represents shares of a foreign company traded on U.S. stock exchanges. It allows investors to buy and sell parts of a foreign company's stock easily, much like purchasing shares of a company based in their own country. ADRs make international investing more convenient and accessible for U.S. investors.
auto-vested financial
"The SRs were granted on March 18, 2026 and will become auto-vested and exercised"
conversion price financial
"Conversion price is reported in Australian Dollars."
The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.
FAQ
What does Telix Pharmaceuticals (TLX) insider Darren Patti report owning in this filing?
Darren Joel Patti reports existing holdings in Telix Pharmaceuticals, including 25,558 Ordinary Shares and 804 American Depositary Receipts. He also lists multiple derivative awards, such as Performance Share Appreciation Rights and Share Rights over tens of thousands of underlying ordinary shares at specified exercise prices and vesting dates.
How are Telix (TLX) American Depositary Receipts treated in this insider report?
The report shows 804 American Depositary Receipts held directly by the insider. A footnote explains that each ADR is convertible at any time, at the holder’s election, into one ordinary share of Telix Pharmaceuticals and that the ADRs themselves have no expiration date.